EP1590449A2 - Lymphocytes t suppresseurs icos+ - Google Patents
Lymphocytes t suppresseurs icos+Info
- Publication number
- EP1590449A2 EP1590449A2 EP04706580A EP04706580A EP1590449A2 EP 1590449 A2 EP1590449 A2 EP 1590449A2 EP 04706580 A EP04706580 A EP 04706580A EP 04706580 A EP04706580 A EP 04706580A EP 1590449 A2 EP1590449 A2 EP 1590449A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- icos
- suppresser
- obtainable
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 124
- 210000004027 cell Anatomy 0.000 claims abstract description 118
- 230000004940 costimulation Effects 0.000 claims abstract description 40
- 230000000735 allogeneic effect Effects 0.000 claims abstract description 34
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims abstract description 29
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims abstract description 29
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 22
- 102000004127 Cytokines Human genes 0.000 claims abstract description 20
- 108090000695 Cytokines Proteins 0.000 claims abstract description 20
- 101150013553 CD40 gene Proteins 0.000 claims abstract description 17
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims abstract description 17
- 230000004044 response Effects 0.000 claims abstract description 17
- 230000035755 proliferation Effects 0.000 claims abstract description 16
- 230000016396 cytokine production Effects 0.000 claims abstract description 14
- 230000000139 costimulatory effect Effects 0.000 claims abstract description 9
- 230000004913 activation Effects 0.000 claims abstract description 7
- 239000003446 ligand Substances 0.000 claims abstract description 7
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 52
- 238000004519 manufacturing process Methods 0.000 claims description 26
- 230000002950 deficient Effects 0.000 claims description 19
- 230000000903 blocking effect Effects 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 16
- 230000003993 interaction Effects 0.000 claims description 16
- 230000005867 T cell response Effects 0.000 claims description 13
- 230000028993 immune response Effects 0.000 claims description 12
- 230000031261 interleukin-10 production Effects 0.000 claims description 11
- 230000006052 T cell proliferation Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 206010011968 Decreased immune responsiveness Diseases 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 7
- 238000002054 transplantation Methods 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 4
- 238000001415 gene therapy Methods 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 230000000172 allergic effect Effects 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 238000011160 research Methods 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 abstract description 34
- 108010002350 Interleukin-2 Proteins 0.000 abstract description 34
- 210000003289 regulatory T cell Anatomy 0.000 abstract description 18
- 230000000638 stimulation Effects 0.000 abstract description 15
- 108020004999 messenger RNA Proteins 0.000 abstract description 12
- 108010002616 Interleukin-5 Proteins 0.000 abstract description 10
- 238000000338 in vitro Methods 0.000 abstract description 9
- 230000002062 proliferating effect Effects 0.000 abstract description 8
- 230000001629 suppression Effects 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 230000005923 long-lasting effect Effects 0.000 abstract description 3
- 230000018711 interleukin-13 production Effects 0.000 abstract description 2
- 230000003704 interleukin-23 production Effects 0.000 abstract description 2
- 230000022023 interleukin-5 production Effects 0.000 abstract description 2
- 230000001404 mediated effect Effects 0.000 abstract description 2
- 238000013518 transcription Methods 0.000 abstract description 2
- 230000035897 transcription Effects 0.000 abstract description 2
- 230000004075 alteration Effects 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 16
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 16
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 16
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 230000006698 induction Effects 0.000 description 11
- 102100037850 Interferon gamma Human genes 0.000 description 10
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 7
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 7
- 108090000176 Interleukin-13 Proteins 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000004073 interleukin-2 production Effects 0.000 description 6
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 230000000961 alloantigen Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100029091 Exportin-2 Human genes 0.000 description 2
- 101710147878 Exportin-2 Proteins 0.000 description 2
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 2
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 2
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 2
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 2
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 2
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 2
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000004046 hyporesponsiveness Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000009711 regulatory function Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000024664 tolerance induction Effects 0.000 description 2
- BPVHBBXCESDRKW-UHFFFAOYSA-N 5(6)-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21.C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BPVHBBXCESDRKW-UHFFFAOYSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 108010045634 B7 Antigens Proteins 0.000 description 1
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- DSIFMINXCSHZPQ-UHFFFAOYSA-M FUN-1 Chemical compound [I-].S1C2=CC=CC=C2[N+](C)=C1C=C(C1=CC=CC=C11)C=C(Cl)N1C1=CC=CC=C1 DSIFMINXCSHZPQ-UHFFFAOYSA-M 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 1
- -1 IL- 13 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100034924 T-lymphocyte activation antigen CD86 Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000012178 germinal center formation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 230000007302 negative regulation of cytokine production Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
Definitions
- the invention relates to the generation and use of regulatory T cells, more particularly suppresser T cells that are identifiable from a population of T cells based on the expression of a particular marker.
- Regulatory T cells have an essential role in the control of immune responses, prevention of autoimmune diseases and tolerance induction after transplantation (Sakaguchi, S., N. et al. 2001. Immunol Rev 182: 18, Roncarolo, M. Get al. 2001. Immunol Rev 182:68 and Shevach, E. M. 2002. Nat Rev Immunol 2:389).
- Several types of regulatory T cells have been described, including CD4 + CD25 + natural suppressor T cells and Trl cells which produce IL-10 and TGF- ⁇ (4). While CD4 + CD25 + cells are generated in the thymus (Sakaguchi, S., N. et al. 2001.
- costimulation blockade with anti-CD40/CD80/CD86 was interpreted as being based on anergy induction (Nan Gool, Set al. 1999. Eur J Immunol 29:2367).
- An alternative hypothesis is, however, that the costimulation blockade induces or activates a regulatory cell population, which suppresses the activity of the other cells.
- ⁇ on-proliferating IL-10-producing "anergic" cells have also been found in other in vitro (Jonuleit, H., et al. 2000. J Exp Med 192: 1213) and in vivo ( Jooss, K., et al 2001.
- ICOS is expressed on activated T cells, and its ligation upregulates a number of membrane molecules like CD 154 and enhances T cell proliferation, secretion of cytokines, and helper function for antibody secretion by B cells Hutloff, A., A. et al. 1999 Nature 397:263, Yoshinaga, S. K., et al. 1999. Nature 402:827 and Beier, K. Cet al.. 2000. Eur J Immunol 30:3707). Unlike CD28 ligation, ICOS ligation does not upregulate the production of IL-2 but superinduces the synthesis of IL-10.
- antibodies refers to immunoglobulin molecules and antigen-binding portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds ("immunoreacts with") an antigen.
- the simplest naturally occurring antibody e.g., IgG
- the natural immunoglobulins represent a large family of molecules that include several types of molecules, such as IgD, IgG, IgA, IgM and IgE.
- the term also encompasses hybrid antibodies, or altered antibodies, and fragments thereof, including but not limited to Fab fragment(s), and Fv fragment. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a naturally-occurring antibody. These fragments are also termed "antigen-binding fragments".
- binding fragments encompassed within the term "antigen-binding fragments” include but are not limited to (i) an Fab fragment consisting of the VL, VH, CL and CHI domains; (ii) an Fd fragment consisting of the VH and CHI domains; (iii) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (iv) a dAb fragment (Ward et al., (1989) Nature 341 :544- 546) which consists of a VH domain; (v) an isolated complimentarity determining region (CDR); and (vi) an F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region.
- a synthetic linker can be made that enables them to be made as a single protein chain (known as single chain Fv (scFv); Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) PNAS 85:5879-5883) by recombinant methods.
- single chain antibodies are also encompassed within the term "antigen-binding fragments".
- Preferred antibody fragments are those which are capable of crosslinking their target antigen, e.g., bivalent fragments such as F(ab').sub.2 fragments.
- an antibody fragment which does not itself crosslink its target antigen e.g., a Fab fragment
- a secondary antibody which serves to crosslink the antibody fragment, thereby crosslinking the target antigen.
- Antibodies can be fragmented using conventional techniques as described herein and the fragments screened for utility in the same manner as described for whole antibodies.
- An Fab fragment of an immunoglobulin molecule is a multimeric protein consisting of the portion of an immunoglobulin molecule containing the immunologically active portions of an immunoglobulin heavy chain and an immunoglobulin light chain covalenfly coupled together and capable of specifically combining with an antigen.
- Fab fragments can be prepared by proteolytic digestion of substantially intact immunoglobulin molecules with papain using methods that are well known in the art. However, a Fab fragment may also be prepared by expressing in a suitable host cell the desired portions of immunoglobulin heavy chain and immunoglobulin light chain using methods disclosed herein or any other methods known in the art.
- An Fv fragment of an immunoglobulin molecule is a multimeric protein consisting of the immunologically active portions of an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region covalently coupled together and capable of specifically combining with an antigen.
- Fv fragments are typically prepared by expressing in suitable host cell the desired portions of immunoglobulin heavy chain variable region and immunoglobulin light chain variable region using methods described herein and/or other methods known to artisans in the field.
- An antibody of the invention is further intended to include bispecific and chimeric molecules having a desired binding portion. Also encompassed within the term "antibodies" are vertebrate antibodies, hybrid antibodies or chimeric antibodies.
- monoclonal antibody refers to an antibody composition having a substantially homogeneous antibody population. It is not intended to be limited as regards to the source of the antibody or the manner in which it is made. Monoclonal antibodies are highly specific, being directed against a single antigenic site. In contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
- the present invention involves a method to generate suppresser T cells, comprising 1) collecting from a mammal body fluid or tissue which comprises T cells, 2) allogeneic activation said T cells under a suppressed costimulation condition or under a costimulation-deficient condition, 3) using ICOS expression as a marker to identify a subpopulation of suppresser T cells and 4) isolating said ICOS+ suppresser cells.
- T cells can be allogeneic activated by co-stimulation-deficient antigen-presenting cells.
- the T cells can be allogeneic activated by antigen-presenting cells in the absence or substantially reduced costimulatory signals of CD40, CD80 and CD86 and the costimulatory signals of CD40, CD80 and CD86 van be removed or substantially removed by blocking the CD40, CD80 and CD86 ligands on said antigen-presenting cells.
- a method to block the CD40, CD80 and CD86 ligands on the antigen-presenting cells can be by inhibiting antibodies or binding fragments there of. Such antibody fragments may be Fab or Fab' fragment of said antibody or single chain antibodies.
- the ICOS+ suppresser cells can be further selected on their IL-10 production or the dependence of their IL- 10 production on the ICOSL- ICOS interaction or they can be selected on their anergy of proliferation upon allogeneic triggering or in a mixed lymphocyte reaction (MLR) test.
- MLR mixed lymphocyte reaction
- Yet another possibility to further select the ICOS+ suppresser cells is on their anergy of Thl or Th2 cytokines production upon allogeneic triggering or in a mixed lymphocyte reaction (MLR) test or on the reduced cytokine production on restimulated of said cells.
- This embodiment can further comprise expanding the cells to clinically relevant numbers.
- Another embodiment preferred is the isolated ICOS+ suppresser T cell or pure cultures of said the isolated ICOS+ suppresser T cell, which are generated and/or selected by the previous embodiment.
- the isolated ICOS+ suppresser T cells of this invention are used to suppress specifically the immune response of alloantigenic-reactive cells. They may be used to suppress responses of primed T cells or to suppress responses of naive T cells.
- the ICOS+ suppresser cells of present invention can also be used to suppress T cell proliferation or to suppress the production of TH1 or TH2 cytokines in stimulated or restimulated T cells.
- Yet another preferred embodiment of present invention is the use of the ICOS+ suppresser cells of the present invention as a research tool to ex vivo investigate the immune system.
- the ICOS+ suppresser T cells of present invention are used in a treatment of a mammal to inhibit T cell proliferation.
- the ICOS+ suppresser T cells of present invention are used in a treatment of a mammal to inhibit T cell response to modulate an immune response. Such treatment can be down regulate allergic immune responses.
- Yet another preferred embodiment is the use of ICOS+ suppresser T cells obtainable by the method of present invention in a treatment mammal to inhibit T cell response associated with chronic inflammatory disease or chronic infectious diseases.
- Another embodiment is to use of ICOS+ suppresser T cells obtainable by the method of present invention in a treatment of a mammal to inhibit T cell response associated associated with an autoimmune disease or with asthma.
- the ICOS+ suppresser T cells obtainable by the method of present invention are used to manufacture of a product for the treatment or prevention of an autoimmune disease, to manufacture of a medicament for the treatment or prevention of an immune response after tissue or organ transplantation, to manufacture of a medicament for the treatment or prevention of an immune response after gene therapy, to manufacture of a medicament for the treatment of an allergic response or to manufacture of a medicament for the treatment of chronic inflammatory disease or chronic infectious diseases.
- Example 1 Monoclonal antibodies and reagents
- Anti-CD80 mAb B7-24 (IgG2a) was produced at Innogenetics (Gent, Belgium) (de Boer, M. et al. 1992. Eur J Immunol 22:3071.).
- Anti-CD86 mAb FUN-1 (IgG2a) was obtained from BD Pharmingen (San Diego, CA).
- Monoclonal antibody 5D12 (ATCC, Manassas, VA) is a blocking mAb to CD40 (Kwekkeboom, J., et al. 1994. Eur J Immunol 24:508).
- the anti-ICOS mAb F44 (IgGl), unlabelled and PE labelled, and the anti-ICOSL mAb HIL-131 (IgGl) were produced by R. Kroczek (Berlin, Germany).
- HIL131 is a blocking antibody (Khayyamian, S., et al. 2002. Proc Natl Acad Sci U S A 99:6198).
- the mAb 2A11 (IgGl) was used as an idiotype control antibody.
- a blocking anti-ILlO receptor mAb (37607.1 1) was obtained from R&D (Minneapolis, MN).
- Anti-CD3, -CD25, -HLA-DR, -CD45RO or isotype control mAbs were purchased from Becton Dickinson and were directly coupled to FITC, PE or PERCP.
- FITC FITC
- PE FITC
- PE FITC
- PERCP recombinant IL-2
- rIL-2 recombinant IL-2
- Boehringer Mannheim Mannheim, Germany
- anti-Tac mAb Zenapax from Roche Pharma, Reinach, Switzerland
- anti-Mik ⁇ l BD Pharmingen
- PBMC Peripheral blood mononuclear cells
- PBMCr responder PBMC
- PBMCs allogeneic irradiated (30 Gy) stimulator PBMC
- MLR primary mixed lymphocyte reactions
- APC costimulation-deficient antigen presenting cells
- PBMCr were harvested, washed in PBS (Boehringer Ingelheim Bioproducts, Heidelberg, Germany) and resuspended in medium. After 2 days, cells were restimulated during 4 days (secondary MLR) with irradiated freshly isolated PBMCs at a R:S ratio of 1 :1 in the absence or presence of blocking mAb as further indicated. In some experiments the cells were again harvested after this secondary MLR, washed and kept in culture for 2 days. After 2 days, these cells were restimulated with irradiated freshly isolated PBMCs in the absence of mAb during another 4 days (tertiary MLR). All restimulations were done with fresh cells from the same donor as in the primary MLR.
- T cell proliferation assay In some experiments responder T cells were further purified before start of the primary stimulation using a complement-mediated depletion of all non-T cells with lympho-KWIK-T (One Lambda Inc, Los Angeles, CA) as described (Ceuppens, J. et al. 1988. J Immunol 141 :3868).
- Example 3 T cell proliferation assay
- CFSE 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester
- PBMCr One million prestimulated PBMCr were mixed with 10 6 irradiated PBMCs in 1 ml medium in a flat-bottomed 24-well plate. Supernatants were taken at day 4. Cytokines were determined by sandwich ELISA technique, using combinations of unlabelled and biotin- or enzyme-coupled mAb to different epitopes of each cytokine (IL-2, IL-5, IL- 13, IL-10 and IFN- ⁇ : mAb from BD Pharmingen)
- Transwell experiments were performed in 24-well plates. 10 -.6 responder T cells were stimulated with 10 6 irradiated PBMC. In addition, lxlO 5 ICOS + or ICOS " cells derived from priming conditions in the presence of blocking antibodies, were either added directly to the culture or were placed in transwell chambers (Cell Culture Insert, 1 ⁇ m; Becton Dickinson) with additional lxlO 5 irradiated stimulator cells.
- Example 6 Cell sorting
- TCCCTGGGTCTTAAGTGAAAGTTT for the reverse primer , resulting in a 128 bp amplicon.
- the sequence of the IL-2 probe was TTTTACATGCCCAAGAGGCCACAGAACT.
- the sequences of the primers and probe for ⁇ -actin have been previously reported (32). All primers and probes were designed with the assistance of the computer program Primer Express (AB) and purchased from Eurogentec (Seraing, Belgium).
- Primer Express AB
- the 5'-nuclease activity of the Taq polymerase was used to cleave a nonextendable dual-labelled fluorogenic probe. Fluorescent emission was measured continuously during the PCR reaction.
- PCR amplifications were performed in a total volume of 25 ⁇ l containing 5 ⁇ l cDNA, 12.5 ⁇ l Universal PCR Master Mix, no AmpErase® UNG (AB), 100-300 nM concentrations of each primer and 200 nM concentrations of the corresponding detection probe.
- Each PCR amplification was performed in triplicate wells using the following conditions: 94°C for 10 min, followed by 40 or 45 cycles at 94°C for 15 s and 60°C for 1 min.
- cDNA plasmid standards consisting of purified plasmid DNA specific for each individual target, were used to quantify the target gene in the unknown samples, as described (Giulietti, A., et al. 2001. Methods 25:386). All results were normalised to ⁇ -actin to compensate for differences in the amount of cDNA in all samples.
- PBMCr irradiated allogeneic PBMC
- PBMCs irradiated allogeneic PBMC
- anti-CD40/CD80/CD86 costimulation-deficient condition
- Fig. 1 restimulation of T cells after the control primary culture induced proliferation (Fig. 1 A) and production of IFN- ⁇ (Fig. IB), IL-5 (Fig. 1C) and IL-13 (Fig. ID), whereas T cells after the costimulation-deficient primary culture failed to proliferate, and failed to produce cytokines except IL-10 (Fig. IE).
- CFSE labelling of the responder cells was also used as a method to simultaneously evaluate proliferation and marker expression.
- proliferating cells CFSE is diluted and thus the proliferating cells can be distinguished from non-proliferating cells on the basis of fluorescence intensity (Lyons, A. B., and C. R. Parish. 1994. J Immunol Methods 171 :131.).
- Our results confirmed that in the absence of costimulation, no T cell proliferation occurred, although the expression of ICOS and CD25 was induced on a subset of the cells (Fig 2). In the control situation, expression of ICOS and CD25 is predominant on the proliferating T cells (Fig 2).
- ICOS+ cells are anergic and block the primary and secondary MLR
- ICOS + and ICOS " cells were separated on a FACSVantage, after the primary MLR with costimulation-deficient APC (Fig. 3). Both subsets were then restimulated in a secondary MLR. There was a marked difference between ICOS + versus ICOS " cells in their functional response. Whereas the total (non-sorted) cell population and sorted ICOS + cells did not proliferate and did not produce IFN- ⁇ , IL-5 and IL-13 upon restimulation, ICOS " cells had a normal proliferative response in a secondary MLR (Fig 4), and they produced cytokines in amounts comparable to the production by control primed T cells.
- ICOS + anergic T cells strongly suppressed the proliferative response of control primed T cells during a secondary MLR. They also suppressed naive T cell proliferation in a primary MLR. We therefore conclude that ICOS + anergic cells have properties of regulatory T cells.
- T cell activation by allogeneic costimulation-deficient APC results in the expression of ICOS on a non-proliferating subpopulation of the T cells.
- ICOS + cells upon restimulation, appear to be anergic (i.e. non-proliferating, no Thl and Th2 cytokine production), but they produce IL-10 and they suppress the response of the reciprocal ICOS- cells.
- this particular subpopulation also suppresses the activation of primed or naive T cells in response to allogeneic triggering.
- IL-10 nor ICOS triggering are required for the suppressive activity of these cells, which rather inhibit IL-2 mRNA formation and IL-2 production by responder T cells in a cell contact dependent way.
- Costimulation-deficient APC in our experiments were generated by adding blocking mAb towards three important costimulatory signals (CD80, CD86 and CD40) in the primary MLR, and the rationale for this has previously been discussed extensively (Van Gool, S. et al. 1996. Immunol Rev 153:47.).
- the advantage of this system is that it is well defined and reproducible as a model.
- the activation of ICOS+ regulatory T cells under costimulation deficient conditions implies that these T cells do not require signals from B7 or CD40. It is most likely that these cells are present in blood in a resting memory state, and that allogeneic triggering without costimulation leads to their activation.
- IL-10 has been shown to block alloantigen responses during MLR and is considered as the main cytokine for induction and maintenance of anergy or tolerance (Groux, H., et al. 1996. J Exp Med 184:19; Steinbrink, K. et al. 1997. J Immunol 159:4772 and Akdis, C. A., et al. 1998. J Clin Invest 102:98.).
- Our experimental model did not reveal a functional effect of the high IL-10 production by the ICOS + anergic cells. Several other mechanisms can be considered.
- ICOS + anergic T cells can produce other cytokines with regulatory properties like TGF- ⁇ , although the role of TGF- ⁇ in regulatory T cell functioning remains controversial (Shevach, E. M. 2002. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389). However, transwell experiments did not support a functional role of any suppressive soluble cytokine in preventing the T cell responses and rather suggests the need for cell-cell contact. ICOS + anergic T cells may directly affect responder T cell through cell contact-dependent mechanisms (similar to CD4 + CD25 + cells). Importantly, we could demonstrate that the anergic regulatory cells do not simply compete for IL-2 with responding T cells.
- ICOS + T reg suppress by cell-cell contact and they suppress IL-2 mRNA formation and IL-2 production by responder cells, rather than consuming the IL-2 from the responder cells.
- ICOS expression is dependent on cell activation and ICOS is a marker for effector T cells (Lohning, M., A. et al. 2003. J Exp Med 197: 181).
- ICOSL - ICOS interaction is important in the activation and function of effector T cells in general, and induces CD28-independent T cell proliferation and cytokine production, especially IL-10 production, along with production of Thl and Th2 cytokines (Hutloff, A., et al. 1999 Nature 397:263 , Beier, K.
- ICOS might be an amplifier of the function of regulatory T cells. ICOS therefore can not be considered as a marker for regulatory T cells in general, but rather as a marker for their "effector" function. ICOS expression on activated regulatory T cells provides a tool to recognize and isolate them after in vitro stimulation in the absence of costimulation. Administration of in vitro generated and purified T cells with this particular phenotype and functional role, can be used as a therapeutic regimen in the prevention and/or downmodulation of autoimmune, alloreactive or allergic immune responses.
- T cells were primed with allogeneic PBMCs and then restimulated with PBMCs from the same donor, in the absence or presence of autologous ICOS+ or ICOS- T cells (induced and sorted as explained in the legend to fig 3). Cytokine production was measured by ELISA.
- ICOS+ or ICOS- cells were either in direct contact to the responder cells or separated by a transwell membrane.
- PBMCr peripheral blood mononuclear cells
- primary MLR allogeneic irradiated PBMCs
- PBMCr were then restimulated '"secondary MLR" during 4 days with freshly isolated and irradiated PBMCs from the same donor as in the primary MLR.
- Figure 2 Induction of ICOS and CD25 expression on a subpopulation of T cells in the MLR with costimulation blockade.
- CFSE-labelled T cells were stimulated with irradiated allogeneic PBMCs in the absence or presence of anti-CD40/CD80/CD86 mAbs.
- cells were collected and stained for CD25, ICOS and CD3.
- Expression of CD25 and ICOS was evaluated on CD3 positive cells. Quadrants were determined on the basis of control stainings with isotype labelled mAbs. Nonproliferating cells retain CFSE intensity as in control nonstimulated T cells, while prolifrating cells progressively loose CFSE labeling. Data shown is representative for 3 separate experiments.
- PBMCr stimulated with PBMCs in the presence of anti-CD40/CD80/CD86 for 7 days were rested in medium for 2 days, and were then sorted with FACSVantage in ICOS + and ICOS " populations with a gate on the lymphocyte population.
- Dot plots of the staining with (A) PE- labelled isotype control or (B) PE-labelled anti-ICOS mAb before and (C) after the sorting procedure are shown. The results are representative for 9 experiments.
- PBMCr were cultured with allogeneic PBMCs under constimulation blockade conditions, and IC ⁇ S + and ICOS ' cell populations were then sorted as described for Fig. 3. These cells were added at a 1/10 ratio to MLR of either control primed T cells (filled symbols), or naive unprimed T (open symbols), both stimulated with allogeneic PBMCs. The mean SI of proliferation in the MLR of 8 different experiments are shown. The black bar represents the mean of the condition.
- PBMCr were prestimulated during 7 days with PBMCs in the absence of presence of anti- CD40/CD80/CD86 as in Figl. After 2 days of rest, PBMCr were restimulated during 4 days with PBMCs in the absence or presence of anti-ICOSL mAb or control mAb (20 ⁇ g/ml) as indicated. After 4 days the cells were washed and resuspended in medium alone and rested again for 2 days. They were then restimulated (tertiary MLR) with freshly isolated and irradiated PBMCs each time from the same donor as in the primary and secondary MLR.
- T cells were cultured with allogeneic PBMCs under constimulation blockade conditions, and ICOS + and ICOS " cell populations were prepared as described in Fig. 3. ICOS + or ICOS " cells were added at a 1/10 ratio to MLR of control primed T cells and restimulated with allogeneic PBMCs.
- A After 24 hours supematants were collected and IL-2 production was measured by ELISA. In these cultures IL-2 consumption was prevented by addition of mAb to CD25 and CD122.
- B At different time points after restimulation, mRNA levels of IL-2 were quantified by real-time RT-PCR.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Les cellules de présentation d'antigène (APC) humaines, sur lesquelles les ligands costimulateurs CD40, CD80 et CD86 sont bloqués par exemple par des anticorps, ne peuvent pas activer complètement des lymphocytes T allogéniques in vitro. Au lieu de cela, elles induisent une altération fonctionnelle des lymphocytes T de longue durée avec une carence en ce qui concerne la production de IL-2, IL-5 et IL-13 lors de la restimulation allogénique. Selon la présente invention, malgré le blocage de la costimulation pendant la stimulation allogénique in vitro, une sous-population de lymphocytes T répondeurs non proliférants est activée pour exprimer des lymphocytes ICOS. Le retrait de ces lymphocytes T exprimant les lymphocytes ICOS rétablit la capacité des lymphocytes ICOS- réciproques à proliférer et à produire des cytokines Th1 et Th2 après la restimulation allogénique. Les lymphocytes ICOS+ sont, en outre, anergiques en ce qui concerne la prolifération et la production des cytokines Th1 et Th2. Cependant, ces lymphocytes peuvent produire de l'IL-10, et ils suppriment les réponses allogéniques des lymphocytes T à amorce ou naïfs par inhibition de la transcription de l'ARNm de l'IL-2. La suppression n'est pas médiée par l'IL-10 mais dépend du contact lymphocyte-lymphocyte. Il est ainsi possible d'activer un sous-type de lymphocytes T régulateurs dans le sang humain en l'absence de signaux costimulateurs émis par CD40, CD80 et CD86, et ces lymphocytes T peuvent être identifiés par l'expression de ICOS après activation.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0302167 | 2003-01-30 | ||
GBGB0302167.2A GB0302167D0 (en) | 2003-01-30 | 2003-01-30 | T cell phenotype |
PCT/BE2004/000017 WO2004067697A2 (fr) | 2003-01-30 | 2004-01-30 | Lymphocytes t suppresseurs icos+ |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1590449A2 true EP1590449A2 (fr) | 2005-11-02 |
Family
ID=9952134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04706580A Withdrawn EP1590449A2 (fr) | 2003-01-30 | 2004-01-30 | Lymphocytes t suppresseurs icos+ |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1590449A2 (fr) |
GB (1) | GB0302167D0 (fr) |
WO (1) | WO2004067697A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2293667A4 (fr) * | 2008-05-27 | 2012-07-18 | Kyowa Hakko Kirin Co Ltd | Anticorps du récepteur de l'interleukine 10 (il-10r) et méthodes d'utilisation |
CN113341161A (zh) * | 2021-06-10 | 2021-09-03 | 苏州大学附属第一医院 | Icos/icosl在诊治变态反应性皮肤病中的应用 |
CN113981031A (zh) * | 2021-11-01 | 2022-01-28 | 山西中医药大学 | 一种新型t细胞功能检测方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1241249A1 (fr) * | 2001-03-12 | 2002-09-18 | Gerold Schuler | Lymphocytes T CD4+CD25+ régulateurs provenant du sang humain |
JP2004527263A (ja) * | 2001-05-30 | 2004-09-09 | フォンダツィオーネ テレソン | 免疫抑制活性を有するエクスビボ単離cd25+cd4+t細胞とその使用 |
-
2003
- 2003-01-30 GB GBGB0302167.2A patent/GB0302167D0/en not_active Ceased
-
2004
- 2004-01-30 EP EP04706580A patent/EP1590449A2/fr not_active Withdrawn
- 2004-01-30 WO PCT/BE2004/000017 patent/WO2004067697A2/fr not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO2004067697A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004067697A3 (fr) | 2004-09-16 |
WO2004067697B1 (fr) | 2004-11-18 |
GB0302167D0 (en) | 2003-03-05 |
WO2004067697A2 (fr) | 2004-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008201685B2 (en) | CD4+CD25+ regulatory T cells from human blood | |
Ramasamy et al. | The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function | |
Witsch et al. | ICOS and CD28 reversely regulate IL‐10 on re‐activation of human effector T cells with mature dendritic cells | |
Godfrey et al. | Cord blood CD4+ CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function | |
Tang et al. | Distinct roles of CTLA‐4 and TGF‐β in CD4+ CD25+ regulatory T cell function | |
Li et al. | New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+ CD4+ regulatory T cells | |
Cardona et al. | Staphylococcal enterotoxin B inhibits regulatory T cells by inducing glucocorticoid-induced TNF receptor-related protein ligand on monocytes | |
Weyand et al. | Functional properties of CD4+ CD28− T cells in the aging immune system | |
Koenen et al. | CD27/CFSE-based ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells | |
Leon et al. | Immunogenicity of biliary epithelium: investigation of antigen presentation to CD4+ T cells | |
CA3081583A1 (fr) | Recepteurs chimeriques a base de complexe majeur d'histocompatibilite et utilisations associees pour le traitement de maladies auto-immunes | |
Ma et al. | Adoptive transfer of CD4+ CD25+ regulatory cells combined with low-dose sirolimus and anti-thymocyte globulin delays acute rejection of renal allografts in Cynomolgus monkeys | |
AU2002257648A1 (en) | CD4+CD25+ regulatory T cells from human blood | |
US10006901B2 (en) | CD4+CD25+ regulatory T cells from human blood | |
Horwitz et al. | Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo | |
US7527972B2 (en) | Uses of bispecific antibody coated dendritic cells pulsed with antigens and GM-CSF in immune regulation | |
Unutmaz et al. | Human naive T cells activated by cytokines differentiate into a split phenotype with functional features intermediate between naive and memory T cells | |
WO2007033291A2 (fr) | Lymphocytes t cd8+ regulateurs induits par des anticorps anti-cd3 | |
CA2601398A1 (fr) | Procede de prevention du rejet d'un tissu transplante | |
Vermeiren et al. | Human T cell activation by costimulatory signal-deficient allogeneic cells induces inducible costimulator-expressing anergic T cells with regulatory cell activity | |
Zeng et al. | B7-1 and B7-2 differentially control peripheral homeostasis of CD4+ CD25+ Foxp3+ regulatory T cells | |
Ndhlovu et al. | Expanding role of T-cell costimulators in regulatory T-cell function: recent advances in accessory molecules expressed on both regulatory and nonregulatory T cells | |
Beyersdorf et al. | Large‐scale expansion of rat CD4+ CD25+ Treg cells in the absence of T‐cell receptor stimulation | |
Masuyama et al. | A novel costimulation pathway via the 4C8 antigen for the induction of CD4+ regulatory T cells | |
WO2004067697A2 (fr) | Lymphocytes t suppresseurs icos+ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050825 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060620 |